Galderma stock gains 1.33% as late quote tops midday level
Published on 11/06/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGalderma governance and market context
- Shareholders approved all proposals at Galderma's April 22, 2026 Annual General Meeting.
- The approved resolutions included a gross dividend of CHF 0.35 per dividend-bearing share.
- Galderma operates across injectable aesthetics, dermatological skincare and therapeutic dermatology.
Galderma stock traded at 209.75 euros on Lang & Schwarz at 17:40 CET on Friday, November 6, 2026, up 1.33 percent from the 207.00-euro quote cited at 12:35 CET in the latest report. The move provides the fresh market update for investors following the company's governance developments.
Governance remains the main focus
Galderma announced on April 22, 2026, that shareholders had approved all proposals at the Annual General Meeting held earlier that day. The resolutions included a gross dividend of CHF 0.35 per dividend-bearing share and the election or re-election of board members.
The company also said shareholders approved its 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Galderma's announcement said detailed voting results and official minutes would follow on its investor-relations website.
Business spans three dermatology areas
Galderma describes itself as a pure-play dermatology company operating in approximately 90 countries. Its portfolio covers Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Investors can follow the real-time quote of Galderma stock.
The Swiss market environment can be followed through current SMI market reports.
More news and analyses on Galderma stock.
Galderma Group AG
- ISIN: CH1335392721
- Ticker: GALD
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz quote: 209.75 euros at 17:40 CET on November 6, 2026
- Change since latest report: 1.33 percent above 207.00 euros at 12:35 CET on November 6, 2026
